Prolight Diagnostics today announced it has reached assay design freeze for its Psyros™ point-of-care cartridge, marking a major development milestone for the Psyros platform and an important step toward commercialisation.
The design freeze confirms the final assay configuration and performance characteristics, freezing the cartridge chemistry. With this milestone achieved, Prolight can now transition to the final optimization of its manufacturing process, focusing on scalability, consistency, and production efficiency ahead of the upcoming clinical performance study.
“This achievement reflects the strong progress our team has made in turning the Psyros vision into a robust, manufacturable product,” said Aileen McGettrick, CSO of Prolight Diagnostics. “With assay design freeze complete, we can now concentrate on refining manufacturing processes to support large-scale production and, ultimately, broad deployment in point-of-care settings.”
The Psyros platform is designed to deliver rapid, high-quality diagnostic analysis at the point of care, enabling timely clinical decision-making and improved patient pathways. Prolight will provide further updates as it advances through manufacturing optimization and progresses towards the clinical performance study.